The present invention relates to hepatocytes, hepatic progenitor cells, biliary epithelial cells, hepatic sinusoidal endothelial progenitor cells, hepatic sinusoidal endothelial cells, hepatic stellate progenitor cells, hepatic stellate cells and hepatocyte tissue models, and methods for their preparation. The invention also relates to a cell fraction comprising hepatic progenitor cells, hepatic sinusoidal progenitor cells, or hepatic stellate progenitor cells. The present invention also relates to a pharmaceutical composition or kit comprising the cell, hepatocyte tissue model or cell fraction. The present invention also provides a method for screening a liver disease therapeutic agent, a method for evaluating the hepatotoxicity of a drug, an infectious disease model hepatocyte and its preparation method, an infectious disease model tissue and its preparation method, and an infectious therapeutic agent. The present invention relates to a screening method.本発明は、肝細胞、肝前駆細胞、胆管上皮細胞、肝類洞内皮前駆細胞、肝類洞内皮細胞、肝星前駆細胞、肝星細胞及び肝細胞組織モデル、並びにそれらの調製方法に関する。本発明はまた、肝前駆細胞、肝類洞内皮前駆細胞、又は肝星前駆細胞を含む細胞画分に関する。本発明はまた、上記細胞、肝細胞組織モデル若しくは細胞画分を含む医薬組成物又はキットに関する。本発明はまた、肝疾患治療剤のスクリーニング方法、薬剤の肝毒性の評価方法、感染性疾患モデルの肝細胞及びその調製方法、感染性疾患モデル組織及びその調製方法、並びに、感染性治療剤のスクリーニング方法に関する。
